Inflammation and lung cancer: roles of reactive oxygen/nitrogen species
N Azad, Y Rojanasakul, V Vallyathan - Journal of Toxicology and …, 2008 - Taylor & Francis
The lung is a highly specialized organ that facilitates uptake of oxygen and release of
carbon dioxide. Due to its unique structure providing enormous surface area to outside …
carbon dioxide. Due to its unique structure providing enormous surface area to outside …
Epidermal growth factor receptor mutations in non–small-cell lung cancer: Implications for treatment and tumor biology
PA Jänne, JA Engelman, BE Johnson - Journal of clinical oncology, 2005 - ascopubs.org
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
JG Paez, PA Janne, JC Lee, S Tracy, H Greulich… - Science, 2004 - science.org
Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC)
and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene …
and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene …
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu, L Lin, T Takahashi… - Journal of the …, 2005 - academic.oup.com
Background: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these …
receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these …
Erlotinib in lung cancer—molecular and clinical predictors of outcome
Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
Regulation of an ATG7-beclin 1 Program of Autophagic Cell Death by Caspase-8
Caspases play a central role in apoptosis, a well-studied pathway of programmed cell death.
Other programs of death potentially involving necrosis and autophagy may exist, but their …
Other programs of death potentially involving necrosis and autophagy may exist, but their …
High frequency of epidermal growth factor receptor mutations with complex patterns in non–small cell lung cancers related to gefitinib responsiveness in Taiwan
SF Huang, HP Liu, LH Li, YC Ku, YN Fu, HY Tsai… - Clinical Cancer …, 2004 - AACR
Purpose: Epidermal growth factor receptor (EGFR) mutations related to gefitinib
responsiveness in non–small cell lung cancer have been found recently. Detection of EGFR …
responsiveness in non–small cell lung cancer have been found recently. Detection of EGFR …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
R Perez-Soler, JP Delord, A Halpern, K Kelly… - The …, 2005 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the clinical and pathological characteristics of the cutaneous rash secondary to …
Describe the clinical and pathological characteristics of the cutaneous rash secondary to …
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
H Linardou, IJ Dahabreh, D Bafaloukos… - Nature reviews Clinical …, 2009 - nature.com
Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with
advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced …
advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced …